Erratum: Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate (Circulation (2014) DOI: 10.1161/CIRCULATIONAHA.114.013445);Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate

Circulation

Volumn 131, Issue 1, 2015, Pages 82-90

  Zahir, Hamim ^a   Brown, Karen S ^a   Vandell, Alexander G ^a   Desai, Madhuri ^a   Maa, Jen Fue ^a   Dishy, Victor ^a   Lomeli, Barbara ^b   Feussner, Annette ^c   Feng, Wenqin ^a   He, Ling ^a   Grosso, Michael A ^a   Lanz, Hans J ^a   Antman, Elliott M ^d  

^a DAIICHI SANKYO INC   (United States)

^b IQVIA   (United States)

^c CSL BEHRING GMBH   (Germany)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anticoagulants; Hemodynamics; Pharmacology; Thrombin

Indexed keywords

4 FACTOR PROTHROMBIN COMPLEX CONCENTRATE; EDOXABAN; PLACEBO; PROTHROMBIN COMPLEX; THROMBIN; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; PROTHROMBIN COMPLEX CONCENTRATES; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ABDOMINAL DISCOMFORT; ANTICOAGULATION; ARTICLE; BLEEDING; CONTROLLED STUDY; CONTUSION; CROSSOVER PROCEDURE; DISEASE DURATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MUSCLE STRAIN; NAUSEA; NORMAL HUMAN; NOSE OBSTRUCTION; PAIN; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PILONIDAL SINUS; PRIORITY JOURNAL; PROTHROMBIN TIME; PUNCH BIOPSY; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; ADOLESCENT; ADULT; ADVERSE EFFECTS; BLOOD CLOTTING; CLINICAL TRIAL; DRUG EFFECTS; HEMORRHAGE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NEEDLE BIOPSY; TIME; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; BIOPSY, NEEDLE; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROTHROMBIN TIME; PYRIDINES; THIAZOLES; TIME FACTORS; YOUNG ADULT;

EID: 84923903585     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0000000000000154     Document Type: Erratum

References (27)

1. Furugohri T, Honda Y, Matsumoto C, Isobe K, Sugiyama N, Morishima Y, Shibano T. Antithrombotic and hemorrhagic effects of DU-176b, a novel, potent and orally active direct factor Xa inhibitor: A wider safety margin compared to heparins and warfarin. Blood (ASH Annual Meeting Abstracts). 2004;104:1851.
2. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104.
3. Hokusai-VTE Investigators, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406-1415.
4. Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA®(edoxaban) in Japan [press release]. Tokyo, Japan: Daiichi Sankyo; September 26, 2014. http://www.daiichisankyo.com/media-investors/media-relations/press-releases/detail/006189.html Accessed September 29, 2014.
5. Lixiana [package insert]. Tokyo, Japan: Daiichi Sankyo Co. Ltd; 2011.
6. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50:743-753.
7. Coumadin® (warfarin sodium) [package insert]. http://packageinserts.bms.com/pi/pi-coumadin.pdf. Princeton, NJ: Bristol-Myers Squibb; 2011.
8. Weitz J, Eikelboom JW, Samama MM, American College of Chest Physicians. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:120S-51S.
9. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446-451.
10. Laulicht B, Bakhru S, Lee C, Baker C, Jiang X, Mathiowitz E, Costin J, Steiner S. Small molecule antidote for anticoagulants. Circulation. 2012;126:A11395. Abstract.
11. Grottke O, van Ryn J, Spronk HM, Rossaint R. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care. 2014;18:R27.
12. Boehringer Ingelheim's Investigational Antidote for Pradaxa® (dabigatran etexilate mesylate) Receives FDA Breakthrough Therapy Designation [press release]. Ridgefield, CT: Boehringer Ingelheim; June 26, 2014. http://us.boehringer-ingelheim.com/news-events/press-releases/press-release-archive/2014/06-26-14-boehringer-ingelheim-investigational-antidote-pradaxa-dabigatran-etexilate-mesylate-fda-breakthroughtherapy-designation.html Accessed October 6, 2014.
13. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-1579.
14. Franchini M, Lippi G. Prothrombin complex concentrates: An update. Blood Transfus. 2010;8:149-154.
15. Levi M, Moore K, Castillejos C, Kubitza D, Berkowitz S, Goldhaber S, Raghoebar M, Patel, Weitz J, Levy J. Comparison of three- And four-factor prothrombin complex concentrates on the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost. 2014;12:1428-1436.
16. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108:217-224.
17. Herzog E, Kasperit F, Krege W, Pragst I, Morishima Y, Shulte S, Dickneite G. Four-factor prothrombin complex concentrate (4-PCC) effectively reverses edoxaban induced bleeding in a rabbit model of acute injury. Blood. 2013;122:1133.
18. Parasrampuria D, Weilert D, Maa J-F, Dishy V, Kochan J, Shi M, Brown K. Switching from dabigatran or rivaroxaban to edoxaban: A biomarker assessment in healthy subjects. J Thromb Haemost. 2014;12(suppl 1):COA41. Abstract.
19. Brown K, Wickremasingha P, Parasrampuria D, Kochan J, Dishy V, Shi M. The impact of prothrombin complex concentrate on the anticoagulatory effects of edoxaban. J Am Coll Cardiol. 2014;63(12-S):doi:10.1016/S0735-1097(14)62098-2. Abstract.
20. Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint, R. Clinical Review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity. Critical Care. 2011;15;201-209.
21. Beriplex ® P/N 1000 [package insert]. Marburg, Germany: CSL Behring GmbH; 2013. http://labeling.cslbehring.com/PI/CORE/Beriplex/EN/Beriplex-Prescribing-Information.pdf Accessed October 6, 2014.
22. Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood. 2010;116:693-701.
23. Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME. Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: A randomized, placebo-controlled, double-blind, exploratory study. Anesth Analg. 2011;113:703-710.
24. Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, Zhang G, Shi M. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13:331-342.
25. Plitt A, Giugliano RP. Edoxaban: review of pharmacology and key phase I to III clinical trials. J Cardiovasc Pharmacol Ther. 2014;19:409-416.
26. Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost. 2012;107:253-259.
27. Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost. 2007;98:790-797.